Information Bulletin #14 - March 2002
If you would like more information about HCV and HIV
co-infection, and HCV treatment options, you can contact The
Network at (800) 734-7104 or (212) 260-8868. A lot of new
information regarding co-infection and the hepatitis C virus is
becoming available. For example, a recent study showed that
people who are HCV co-infected are more likely to experience
liver toxicity from the drug nevirapine (Viramune) than
HIV-positive people who are not infected with HCV. Protease
inhibitors also seem to have more potential to cause liver damage
in people who are co-infected. Several very important studies
concerning HIV/HCV co-infection and treatment, as well as new
information regarding lactic acidosis and mitochondrial toxicity,
will be available very shortly as well.
Interested individuals who live in New York City, or receive HIV
services of some type in New York are encouraged to contact us
regarding our HIV/HCV education, treatment adherence, and
counseling program. We will send you a full description of the
program, and how it could help HIV-positive individuals to pay
for both HIV and HCV treatments, as well as experimental
treatment programs. The program also offers supportive counseling
to co-infected individuals. Give us a call or e-mail to
network@atdn.org.